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Abstract: Candida auris, a newly-emerging Candida species, is a serious global health threat due to
its multi-drug resistant pattern, difficulty to diagnose, and the high mortality associated with its
invasive and bloodstream infections. Unlike C. albicans, and C. dubliniensis which can form true
hyphae, C. auris grows as yeast or pseudohyphae and is capable of developing biofilms. The reasons
for the inability of C. auris to form true hyphae are currently unknown. Metabolites secreted by
microorganisms, including Candida, are known as important factors in controlling morphogenesis
and pathogenesis. Metabolic profiling of C. auris and C. albicans cultures was performed using gas
chromatography–mass spectrometry (GC–MS). Compared to C. albicans, C. auris secreted several
hyphae-inhibiting metabolites, including phenylethyl, benzyl and isoamyl alcohols. Furthermore, a
biofilm-forming metabolite—tyrosol—was identified. On the other hand, several other biomarkers
identified from C. auris but not from C. albicans cultures may be produced by the organism to overcome
the host immune system or control fungal adaptations, and hence ease its invasion and infections.
The results from this study are considered as the first identification of C. auris metabolic activities as a
step forward to understand its virulence mechanisms.
Keywords: Candida auris; metabolic profiling; GC-MS; morphogenesis; hyphae; yeast
1. Introduction
Candida species, in particular C. albicans, are responsible for most fungal infections in humans.
Although Candida species can cause superficial mucosal and skin infections, they can generate serious
threats to immunocompromised patients, including fatal bloodstream candidiasis [1]. In recent years,
the Centers for Disease Control and Prevention (CDC) has designated C. auris as an emerging serious
global health threat mainly because of its multidrug-resistant pattern associated with high mortality
rate that can reach 60% [2,3], difficulty to diagnose [4] and recent outbreaks in healthcare settings
owing to the yeast persistence as a colonizer on abiotic surfaces [5].
C. auris was first identified in Japan on 2009 [6]. Since then, infections due to C. auris have been
reported from over a dozen countries, including United States, Canada, Colombia, Germany, India,
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Israel, Japan, Kenya, Norway, Pakistan, Spain, South Africa, South Korea, the United Kingdom,
Venezuela, Kuwait and Oman [7]. Phylogenetic analysis indicates that C. auris is a recent and
simultaneous emergent strain in different geographical areas [8]. This yeast can be recovered from
several human specimens, including sterile body fluids, ears, wounds and mucocutaneous swabs.
However, the major manifestation of the infection includes invasive and bloodstream infections [9].
Like other Candida species, there is no indication that it can cause true respiratory, urinary, and skin
and soft tissue infections despite being isolated from such samples [10,11]. Individuals who are at
risk of acquiring C. auris infections include hospitalized and nursing home patients. These patients
usually have comorbidities that is likely to contribute with the multi-drug resistant nature of the
yeast to the lethality of the infection [12]. Importantly, C. auris is often misdiagnosed as C. haemulonii.
Thus, the CDC recommends further testing whenever a diagnosis of C. haemulonii is identified [4].
As C. auris continues to emerge throughout the world, vital measures are required to slow down its
spread and to reduce the environmental contamination in healthcare facilities and to improve diagnosis
of the infection.
C. auris exhibits round-to-ovoid yeast morphology and, in some reports, ability to form
pseudohyphae without the formation of true hyphae [12]. A major strategy used by Candida albicans to
control its morphogenesis is the production of phenotype-switching metabolites [13]. The concentration
of these metabolites increases to a critical threshold, which in turn triggers a morphogenetic regulatory
response [14]. Several C. albicans metabolites, including farnesol, are known to inhibit yeast-to-hyphae
formation [15]. In contrast, C. albicans tyrosol induces filamentation and hence biofilm formation [16].
Other reported hyphae-inhibiting alcohols include phenylethyl [17], isoamyl and benzyl alcohols in
addition to tryptophol [18].
We conducted GC-MS analysis to compare the metabolic profile of C. auris to those of C. albicans.
GC-MS is a powerful technique used to establish a comprehensive quantitative metabolic profiling of
volatile small molecules from any complex biological samples [19]. The results showed that C. auris
produces metabolites consistent with those promoting yeast formation.
2. Results and Discussion
C. auris or C. albicans cultures were extracted and derivatized prior to GC-MS analysis in order to
enhance the appearance of metabolic spectrum and increase the detection limits of the metabolites. The
identified metabolites from Candida cultures were classified in relation to their possible morphogenic
and virulence activities.
2.1. Superior Production of Hyphae-Inhibitory Metabolites by C. auris
It is reported that, C. albicans responds to environmental changes by developing different
polymorphic forms including yeast, pseudo-hyphae and true hyphae [20,21]. Phenotype-switching
metabolites play a critical role in C. albicans morphogenesis [22]. Unlike C. albicans, C. auris grows
readily as yeast form and does not produce true hyphae [3,12,23]. Further reports indicated that
C. auris is capable of forming biofilms [24] and adhering to catheter material [25].
We wanted to investigate if metabolites production by C. auris is consistent with its yeast form, even
when grown under hyphae-promoting conditions. Thus a preliminary study was conducted by growing
C. auris in culture conditions that mimic the development of hyphae in C. albicans (Figure 1). Cell free
supernatants from cultures of C. auris CAU09 and C. albicans were then collected and separately screened
for the presence of similar metabolites using GC-MS analysis (Figure 2A–D). The results showed that C.
auris CAU09 cultures secreted metabolites particularly: 1) aromatic alcohols such as phenylethyl alcohol,
benzyl alcohol, isoamyl alcohol and tyrosol; and 2) acids such as benzoic, benzenacetic, glyceric and
others that were not identified in C. albicans cultures (Figure 2A,B and Figure 3).
Metabolites known to be involved in Candida morphogenic changes were grouped and
their average relative percentages were compared to each other in C. auris CAU09 strain using
Box-and-Whiskers Plots (Figure 4A). The plots showed that there was a significant increase in the
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production of both phenylethyl alcohol (11.39 ± 0.5%) and tyrosol (3.137 ± 0.4). In addition, a less
prominent increase in palmitelaidic acid (1.8 ± 0.34), and at lower extent, benzyl alcohol (0.2 ± 0.06%)
as well as isoamyl alcohol (0.57 ± 0.19%) was detected (Figure 4A and Supplementary Table S1).
Molecules 2019, 24, 399 3 of 12 
 
prominent increase in palmitelaidic acid (1.8 ± 0.34),  t lo er extent, benzyl alcoh l (0.2 ± 0.06%) 
as well as isoamyl alcohol (0.57 ± 0.19%) was d  (Figure 4A and Supplem ntary Table 1). 
 
Figure 1. Growth of C. auris (CAU09) in comparison to C. albicans at biofilm-forming condition at 4 
and 16 h. Candida isolates were cultured at 37 °C in 125 mL Corning culture flasks. 
 
Figure 2. Cont. 
Figure 1. Growth of C. auris (CAU09) in compariso t . albicans at biofilm-forming condition at 4
and 16 h. Candida isolates were cultured at 37 ◦C in 125 mL Corning culture flasks.
Molecules 2019, 24, 399 3 of 12 
 
prominent increase in palmitelaidic acid (1.8 ± 0.34), and at lower extent, benzyl alcohol (0.2 ± 0.06%) 
as well as isoamyl alcohol (0.57 ± 0.19%) was detected (Figure 4A and Supplementary Table 1). 
 
Figure 1. Growth of C. auris (CAU09) in comparison to . albicans at biofilm-forming condition at 4 
and 16 h. Candida isolates were cult red at 37 °C in 125 rning culture fla ks. 
 
Figure 2. Cont. Figure 2. Cont.
Molecules 2019, 24, 399 4 of 12
Molecules 2019, 24, 399 4 of 12 
 
Figure 2. GC-MS chromatograms of Candida cultures extracts. Chromatograms of (A) C. albicans 
ATCC10231 strain compared to (B) C. auris (CAU09) strain. (C) and (D) GC-MS chromatograms of C. 
auris CAU09 at two different growth stages (C) 16 h compared to (D) 4 h incubation periods 
representing the differences in metabolites abundance. CAU09 was used as a representative to C. 
auris strains since all C. auris strains showed a similar pattern of GC-MS analysis (data not shown). 
Cell-free supernatants were collected, extracted by chloroform and derivatized by MSTFA and TMS 
prior to GC-MS analysis using GC-2010 coupled with a GC–MS QP-2010 Ultra. 
The secreted metabolites in CAU09 cultures were further compared at 4 and 16 h incubation 
periods (Figure 2C and D). Both phenylethyl alcohol, and tyrosol, were increased by 10 and 4-fold, 
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were detected in the levels of benzyl and isoamyl alcohols. It is reported that the aforementioned 
alcohols including phenylethyl, benzyl and isoamyl alcohols are hyphae-inhibiting metabolites 
[3,12,23], while tyrosol is a filamentation and biofilm-forming metabolite [16]. The production of 
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strains. In contrast, none of these metabolites was identified in C. albicans ATCC10231 except 
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Table 1). These results indicate that both phenylethyl alcohol and tyrosol and to some extent 
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Figure 2. GC-MS chromatograms of Candida cultures extracts. Chromatograms of (A) C. albicans
ATCC10231 strain compared to (B) C. auris (CAU09) strain. (C) and (D) GC-MS chromatograms
of C. auris CAU09 at two different growth stages (C) 16 h compared to (D) 4 h incubation periods
representing the differences in metabolites abundance. CAU09 was used as a representative to C. auris
strains since all C. auris strains showed a similar pattern of GC-MS analysis (data not shown). Cell-free
supernatants were collected, extracted by chloroform and derivatized by MSTFA and TMS prior to
GC-MS analysis using GC-2010 coupled with a GC–MS QP-2010 Ultra.
The secreted metabolites in CAU09 cultures were further compared at 4 and 16 h incubation
periods (Figure 2C,D). Both phenylethyl alcohol, and tyrosol, were increased by 10 and 4-fold,
respectively, within 16 h of incubation versus 4 h cultures (Figure 2C,D), while little changes were
detected in the levels of benzyl and isoamyl alcohols. It is reported that the aforementioned alcohols
including phenylethyl, benzyl and isoamyl alcohols are hyphae-inhibiting metabolites [3,12,23], while
tyrosol is a filamentation and biofilm-forming metabolite [16]. The production of phenylethyl, benzyl
and isoamyl alcohols is consistent with the yeast form of C. auris.
The aforementioned changes in metabolites were compared among four other C. auris strains
along with C. albicans ATCC10231 (Heatmap in Figure 3, Figure 5A and Supplementary Table S1).
A similar pattern was obtained in all other C. auris strains. Specifically, C. auris strains secreted high
percentages of aromatic alcohols such as phenylethyl alcohol (~7–11%), benzyl alcohol (~0.1–0.2%),
and at a lower extent, isoamyl alcohol. Palmitelaidic acid (~1–2%) was also detected in C. auris strains.
In contrast, none of these metabolites was identified in C. albicans ATCC10231 except decanoic acid
which was detected in very low amount (0.09 ± 0.023) (Figure 5A and Supplementary Table S1).
These results indicate that both phenylethyl alcohol and tyrosol and to some extent palmitelaidic acid
are likely critical C. auris morphogenic metabolites at the tested condition.
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Phenylethyl Alcohol 9.8 9.59 7.097 10.34 11.4 0
Allyl alcohol 0 0.11 0 0 0 0
Isoamyl alcohol 0.057 0.068 0.044 0.097 0.57 0
4-Hydroxybenzyl alcohol 0 0.11 0 0 0 0
Diacetone alcohol 0 0 0 0 0 0.14
3,4-Dimethylbenzyl alcohol 0 0 0 0 0 0.09
Tyrosol 4.245 3.275 3.775 4.425 3.138 0
 Decanoic acid (Capric Acid) 0.754 0.268 0.248 0.403 0.502 0.09
10-Undecenoic acid (undecylenic acid) 0.028 0.034 0.047 0.055 0.345 0
Palmitelaidic acid 0.14 0.51 1.84 0.04 0.75 0
Hexanoic acid (caproic acid) 0.015 0.054 0.082 0.075 0.123 0
Niacin 1.46 0.16 0.29 0.37 0.37 0
Pyrazine derivative 2.26 0.005 0.064 2.507 2.743 0
Palmitelaidic acid 1.02 0.939 2.072 1.133 1.815 0
Benzeneethanamine 5.8 23.59 20.57 11.65 3.76 0
Farnesol 0 0 0 0 0 0
2-Propenoic acid (Acrylic acid) 0.43 0.08 0.39 0.19 0.3 0
3-hydroxy propanoic acid (Hydracrylic acid) 0.29 0.18 0.28 0.55 0.33 0
Methionol (3-(Methylthio)propyl alcohol) 0.099 0.082 0.19 0.918 0.865 0
Propanoic acid 0.025 0.066 0.226 0.24 0.27 11.35
Tryptophol 0.32 0.14 0.19 0.452 0.55 0
Benzoic Acid 0.627 0.252 0.543 1.817 0.977 0
Octanoic acid (Caprylic acid) 0.12 0.06 0.059 0.14 0.117 0
Benzeneacetic acid (phenyl acetic acid) 1.832 0.623 1 1.57 2.37 0
Glyceric acid 1.775 0.898 0.773 0.92 0.988 0
Kojic acid 2.24 0.407 0.5 1.668 1.79 0
Dodecanoic acid (lauric acid) 0.57 0.199 0.157 0.375 0.18 0
Pyrrolo[1,2-a]pyrazine-1,4-dione, hexahydro-3-(2-methylpropyl) 1.32 7.74 0.74 4.6 2.27 0
2-Methylpropanoic acid 0 0.41 1.47 1.43 2.99 0.09
4-Methylvaleric acid 0 0.06 0 0.14 0 0
Propane, 2-methyl-1,2-bis(trimethylsiloxy) 0 0 0.05 0.1 0 0
2-Pyrrolidinone, TMS derivative 0.37 0 0.22 0.38 0 0
(R)-3-Hydroxybutyric acid 0.12 0.07 0.24 0.34 0 0
2-Hydroxy-3-methylbutyric acid 0 0.16 0.31 0.37 0 0
3-Methyl-1,2-bis(trimethylsilyl)butane 0 0 0.11 0.12 0 0
2-Ethoxyethanol 0.15 0 0 0.45 0 0
3,4-Dihydroxy-5-methyl-dihydrofuran-2-one, (D) 0.15 0 0 0.43 0 0
Monoethyl succinate 0 0 0 0.21 0 0
Thiodiglycol 0 0 0 0.18 0 0
Methylsuccinic acid 0.14 0.07 0.28 0.33 0 0.27
2-Hydroxyoctanoic acid 0.42 0.12 0.19 0.2 0 0
Pentanedioic acid 0 0.05 0.27 0.28 0 0.16
3-Bromo-1-propanol 0 0 0 0.88 0 0
4-Hydroxy-5-(hydroxymethyl)oxolan-2-one 0.23 0 0 0.26 0 0
3-Phenyllactic acid 0.23 0.07 0.19 0.2 0 0
3-Hydroxyphenylacetic acid 0.29 0.07 0.12 0.24 0 0
3-Octanol, 2-methyl- 1.12 0 0.24 0.37 0 0
n-Heptadecanol-1 0 0 0 0.55 0 0
Acedoben 0 0 0 0.28 0 0
Indole-5-carboxylic acid 0 0 0 0.14 0 0
Carbonic acid, propargyl 2-ethylhexyl ester 0 0 0 0.11 0 0.19
Stearic acid 6.02 1.26 1 0.38 0 0.17
[1-(3,3-Dimethyloxiran-2-ylmethyl)-3,7-dimethylocta-2,6-dienyl] 0 0 0 2.39 0 0
Methylamine 5.02 0 4.32 1.12 3.73 0.49
Ethylene glycol 1.52 0.05 0.94 0.39 1.19 0.22
3-Methylbutanoic acid 0.34 0.5 1.34 2.92 3.93 0.5
2-Acetoxyacetate 0.7 0.2 0.49 0.93 1 0.38
Lactic Acid 0.53 0.32 0.88 1.29 1.02 0.11
Glycolic acid 0.37 0.22 0.27 0.61 0.45 0.04
Glycerol 1.21 0.47 3.85 3.53 2.07 0.01
Butanedioic acid 1.12 0.79 8.81 5.16 2.82 1.99
Myristic acid 0.5 0.15 0.7 0 0.72 0.15
Palmitic Acid 6.64 1.85 4.65 0.63 0.91 0.57
4-Isopropylphenol 0 0 0 0 0 13.25
Benzene, (1-methylethyl) 0 0 0 0 0 5.9
Ethanone, 1-[4-(1-methylethyl)phenyl] 0 0 0 0 0 2.24
Butanedioic acid 1.12 0.79 8.81 5.16 2.82 0.44
1-Butanone, 2-chloro-3-methyl-1-[4-(1-methylethyl)phenyl] 0 0 0 0 0 0.27
2-Methyl-6-tert-butylphenol 0 0 0 0 0 1.19
Figure 3. Heatmap of major identified metabolites in Candida cultures by GC-MS. Metabolite average
relative percentage of four experimental replicates from two independent biological experiments were
displayed as colors ranging from red to green as shown in the key. The relative percentage of a
metabolite represented in relation to total areas of all detected metabolites in an extract.
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Figure 4. Relative percentages of metabolites produced by C. auris CAU09 cultures. (A) The 
metabolites produced by the organism for the purpose of its morphogenic changes. (B) The 
metabolites produced by the organism for the purpose of protection and colonization. The quantity 
of each metabolite was represented as the relative percentage by measuring the area under the 
peak of each metabolite in relation to the total areas of all other metabolites detected in the extract. 
The data display the mean of the relative percentage ± standard error of the mean. The data was 
graphed using Box-and-Whiskers Plots and analyzed by one-way analysis of variance (ANOVA) 
using Bonferroni's Multiple Comparison Test. P value < 0.05 was considered as significant. The 
standard error represents the mean of 4 replicas of two independent experiments. The level of 
significance was indicated by asterisks. 
Farnesol was absent in both C. auris and C. albicans cultures. The absence of farnesol in C. 
albicans culture is expected, since it is a yeast-to-hyphal inhibitory metabolite [15], and the growth 
condition favored hyphal growth. It is prudent to mention that C. auris harbors a homologue for C. 
albicans farnesyl synthase, the rate-limiting enzyme in farnesol biosynthesis [26], with 79% amino 
acid identity. Equally important, non-albicans species of Candida are known to produce ~8–35 times 
lower levels of farnesol when compared to C. albicans [27]. Therefore, the lack of detection of any 
farnesol could be due to lower limits of production consistent with what is seen with non-albicans 
species. This result indicated that farnesol expression was not required in C. auris culture condition 
under study and hence confirmed that other factors may be involved in maintaining the growth of C. 
auris as yeast form. Importantly, farnesol is known to have reversal effect on tyrosol [16]; and 
production of tyrosol by C. auris was favored at this condition, a condition suitable for biofilm 
development. Collectively, these results indicate that fundamental biological processes are under 
complex positive and negative control by environmental conditions in which these aromatic alcohols 
are secreted. Future studies focusing on gene expression analysis and investigation of transcription 
factors that govern yeast-to-hyphae switch might shed light on the reasons why C. auris lacks the 
ability to form true hyphae. 
Decanoic, 10-undecenoic and palmitelaidic were acid metabolites identified in C. auris cultures 
that have never been detected by other Candida Spp. (Figure 3, 5A and Supplementary Table 1). This 
result raises the possibility of using these acid metabolites as biomarkers to aid in the organism 
diagnosis. The detected metabolites were also reported as hyphae-inhibitory substances [28–30], a 
situation may favor the growth of the organism in the yeast form. 
Figure 4. Relative percentages of metabolites produced by C. auris CAU09 cultures. (A) The metabolites
produced by the organism for the purpose of its morphogenic changes. (B) The metabolites produced
by the organism for the purpose of protection and colonization. The quantity of each metabolite was
represented as the relative percentage by measuring the area under the peak of each metabolite in
relation to the total areas of all other metabolites detected in the extract. The data display the mean of
the relative percentage ± standard error of the mean. The data was graphed using Box-and-Whiskers
Plots and analyzed by one-way analysis of variance (ANOVA) using Bonferroni’s Multiple Comparison
Test. P value < 0.05 was considered as significant. The standard error represents the mean of 4 replicas
of two independent experiments. The level of significance was indicated by asterisks.
Farnesol was absent in both C. auris and C. albicans cultures. The absence of farnesol in C. albicans
culture is expected, since it is a yeast-to-hyphal inhibitory metabolite [15], and the growth condition
favored hyphal growth. It is prudent to mention that C. auris harbors a homologue for C. albicans
farnesyl synthase, the rate-limiting enzyme in farnesol biosynthesis [26], with 79% amino acid identity.
Equally important, non-albicans species of Candida are known to produce ~8–35 times lower levels of
farnesol when compared to C. albicans [27]. Therefore, the lack of detection of any farnesol could be
due to lower limits of production consistent with what is seen with non-albicans species. This result
indicated that farnesol expression was not required in C. auris culture condition under study and
hence confirmed that other factors may be involved in maintaining the growth of C. auris as yeast form.
Importantly, farnesol is known to have reversal effect on tyrosol [16]; and production of tyrosol by
C. auris was favored at this condition, a condition suitable for biofilm development. Collectively, these
results indicate that fundamental biological processes are under complex positive and negative control
by environmental conditions in which these aromatic alcohols are secreted. Future studies focusing on
gene expression analysis and investigation of transcription factors that govern yeast-to-hyphae switch
might shed light on the reasons why C. auris lacks the ability to form true hyphae.
Decanoic, 10-undecenoic and palmitelaidic were acid metabolites identified in C. auris cultures
that have never been detected by other Candida Spp. (Figure 3, Figure 5A and Supplementary Table S1).
This result raises the possibility of using these acid metabolites as biomarkers to aid in the organism
diagnosis. The detected metabolites were also reported as hyphae-inhibitory substances [28–30], a
situation may favor the growth of the organism in the yeast form.
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Figure 5. Comparison of relative percentages of metabolites produced by different C. auris strains. 
(A) Proposed metabolites employed in morphogenic changes. (B) Proposed metabolites produced by 
the organism for the purpose of protection and colonization. The quantity of each metabolite was 
represented as the relative percentage by measuring the area under the peak of each metabolite in 
relation to the total areas of all other metabolites detected in the extract. The data display the mean of 
the relative percentage ± standard error of the mean. The data was analyzed by two-way analysis of 
variance (ANOVA). P value < 0.05 was considered as significant. The standard error represents the 
mean of 4 experimental replicates of two independent biological experiments. The level of 
significance was indicated by asterisks. 
 
Figure 5. Comparison of relative percentages of metabolites produced by different C. auris strains.
(A) Proposed metabolites employed in morphogenic changes. (B) Proposed metabolites produced by
the organism for the purpose of protection and colonization. The quantity of each metabolite was
represented as the relative percentage by measuring the area under the peak of each metabolite in
relation to the total areas of all other metabolites detected in the extract. The data display the mean of
the relative percentage ± standard error of the mean. The data was analyzed by two-way analysis of
variance (ANOVA). P value < 0.05 was considered as significant. The standard error represents the
mean of 4 experimental replicates of two independent biological experiments. The level of significance
was indicated by asterisks.
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2.2. C. auris Produced Auto-Protective/Auto-Toxic Metabolites
Some microbial metabolites exert toxic effects on host cells and/or modulate host immunity in
order to facilitate microbial invasion [31]. C. auris secreted fatty acids such as capric, undecylenic and
palmitelaidic acids (Figures 3, 4A and 5A), known to impair the ability of host natural response to
eliminate microorganisms [32]. C. auris also secreted propanoic acid that can exert immune-suppressive
activity [33] and pyrazine derivative that may help in host-microbe colonization [34] (Figures 4B and
5B). Furthermore, C. auris produced autotoxic metabolites including tryptophol [35], propanoic [36],
benzoic [37], octanoic acid (caprylic acid) [38], benzeneacetic acid (phenyl acetic acid) [37],
glyceric [39], kojic [40,41], dodecanoic (lauric) [42,43] acids and pyrrolo[1,2-a]pyrazine-1,4-dione,
hexahydro-3-(2-methylpropyl) [44] that can facilitate its own growth and hence access more nutrients
(Figures 4B and 5B). Although the production of the aforementioned metabolites was differ between
different C. auris strains, pyrazine derivative, benzeneacetic acid, kojic acid, glyceric acid and benzoic
acid were produced in higher levels when compared to other auto-protective metabolites (Figures
4B and 5B), which may indicate their favored production by the organism. On the other hand, out
of the aforementioned auto-protective metabolites, C. albicans showed production of very high level
of propanoic acid (~11.35 ± 0.24) (Figure 3 and Supplementary Table S1). Autotoxic/auto-protective
metabolites are known to increase nutrient availability and hence allow better colonization of the
pathogenic organism in addition to its immune-suppressive effects [35].
2.3. C. auris Produced Metabolic Fermentation Products, Known for Colonization and Invasion
Within the host, the pathogen must efficiently compete for nutrients with host cells [45] and
its metabolism is affected in a niche-specific fashion [46]. Microbial pathogens produce metabolic
products to overcome the host resistance mechanisms and hence allow the pathogen to colonize
and invade. Such metabolic fermentation products may modulate the host immune system and
change the body temperature or pH [47,48]. Compared to C. albicans, C. auris produced fermentation
metabolic products including hexanoic acid (caproic acid), 2,3-butanediol [49], 2-propenoic acid (acrylic
acid) [50], 3-hydroxypropanoic acid (hydracrylic acid) [51] and the yeast-specific fermentation product
methionol [52] (Figure 3 and Supplementary Table S1).
3. Materials and Methods
3.1. Organisms and Culture Conditions
Five different C. auris clinical isolates were obtained from Centers for Disease Control and
Prevention (CDC, Atlanta, GA, USA). These were CAU-01 (East Asian clade, ear), CAU-03 (African
clade, blood), CAU-05 (South American clade, blood), CAU-07 (South Asian clade, blood), and CAU-09
(South Asian clade, bronchoalveolar lavage [BAL]). C. albicans reference strain ATCC10231 was used as
a control. Candida isolates were allowed to grow separately in yeast nitrogen base (YNP) supplemented
with 2% glucose at 37 ◦C for 16 h. Cells were washed with phosphate buffered saline (PBS), and
the inoculums adjusted to 5 × 106 yeast/mL with RPMI-1640 (Sigma-Aldrich, Torrance, CA, USA)
using hemacytometer [53]. The cultures were further incubated for 24 h at 37 ◦C in 125 mL Corning
culture flasks, after which cell-free supernatants were collected by filtration using 0.2 µM Whatman
filter paper.
3.2. Preparation of Samples for GC-MS Analysis
The filtered supernatants collected separately from each Candida isolate was extracted with
chloroform (Fisher Scientific, Santa Clara, CA, USA). The chloroform layer was dehydrated over
anhydrous sodium sulphate (Fisher Scientific) followed by evaporation using rotatory evaporator
(Buchi, Essen, Germany). The residue collected from each extracted culture was dissolved in 500 µL
chloroform prior to GC-MS injection. Furthermore, 100 µL of the chloroform extract was derivatized
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by adding 50 µL of N-trimethylsilyl-N-methyl trifluoroacetamide and trimethylchlorosilane (MSTFA +
1% TMS) followed by incubation at 50 ◦C for 30 min prior to GC-MS analysis.
3.3. GC-MS Spectrometry
GC–MS analysis was performed using a QP2010 gas chromatography-mass spectrometer (GC-2010
coupled with a GC–MS QP-2010 Ultra) equipped with an auto-sampler (AOC-20i+s) from Shimadzu
(Tokyo, Japan), using Rtx-5ms column (30 m length× 0.25 mm inner diameter× 0.25 µm film thickness;
Restek, Bellefonte, PA, USA). Helium (99.9% purity) was used as the carrier gas with the column
flow rate of 1 mL/min. The column temperature regime was initially adjusted at 35 ◦C for 2 min;
followed by an increase in a rate of 10 ◦C/min to reach 250 ◦C. The temperature was then increased by
20 ◦C/min until reaching 320 ◦C and kept for 23 min. The injection volume and injection temperature
were 1 µL and 250 ◦C using splitless injection mode, respectively. The mass spectrometer operated in
electron compact mode with electron energy of 70 eV. Both the ion source temperature and the interface
temperature were set at 240 ◦C and 250 ◦C, respectively. The MS mode was set on scan mode starting
from 35 to 450 m/z with a scan speed of 1428. Data collection and analysis were performed using MSD
Enhanced Chemstation software (Shimadzu). Product spectra were identified by comparison of the
measured fragmentation patterns to those found in the NIST 08 Mass Spectral Library.
3.4. Bioinformatics detection of farnesyl synthase protein in C. auris
A local BLAST database of C. auris genome was created using Basic Local Alignment Search Tool
plus (BLAST+) [54]. Farnesyl synthase protein sequence (Accession #KGQ89011) from C. albicans was
downloaded from NCBI and used to search the generated C. auris genome using tblastn command.
The search revealed a sequence with 79% identity within 577 score.
3.5. Statistical analysis
The data was collected and graphed using either Excel to generate the heatmap or Graph Pad
(5.04, La Jolla, CA, USA) for Windows to generate the Box-and-Whiskers Plots and group comparison.
The quantification of metabolites extracts were analyzed by one-way analysis of variance (ANOVA)
using Bonferroni’s Multiple Comparison Test or two-way analysis of variance as indicated per each
graph. P value < 0.05 was considered significant. The standard error represents the mean of 4
replicas of two independent experiments (two experimental replicates per each independent biological
experiment). Each extract was divided into two and extracted separately followed by derivatization
prior to GC-MS analysis.
4. Conclusions
Metabolites produced by microorganisms may be used as communication signals that allow the
microorganisms to share information and hence provide some regulatory responses during infection.
Metabolic profiling can be of great help to identify critical determinant of pathogens and hence
can control disease progression. Candida spp. is known for secreting metabolites that control its
morphogenesis. C. auris is a newly-emergent Candida species that is maintained in the yeast phenotype
during its growing stages. Analysis of C. auris cultures by GC-MS showed that the fungus produces
diverse hyphae-inhibiting metabolites in addition to biofilm-forming tyrosol that are distinct from C.
albicans. The results provided in this research is the first to identify C. auris metabolic profiling; and
thus can shed light on the virulence of this multi-drug resistant yeast and may eventually lead to the
development of new strategies for in deep investigation including gene expression analysis and study
of morphogenesis-regulatory pathways.
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